<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Headache Pain</journal-id><journal-id journal-id-type="iso-abbrev">J Headache Pain</journal-id><journal-title-group><journal-title>The Journal of Headache and Pain</journal-title></journal-title-group><issn pub-type="ppub">1129-2369</issn><issn pub-type="epub">1129-2377</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Milan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3451767</article-id><article-id pub-id-type="publisher-id">49</article-id><article-id pub-id-type="doi">10.1007/s10194-003-0049-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original</subject></subj-group></article-categories><title-group><article-title>Botulinum toxin type A in
prophylactic treatment of migraine headaches: a preliminary
study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Barrientos</surname><given-names>Nelson</given-names></name><address><phone>+562-2734015</phone><fax>+562-2751842</fax><email>nbu@adsl.tie.cl</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Chana</surname><given-names>Pedro</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Dipreca Hospital, Av Vital Apoquindo, 1200 Santiago, Chile </aff></contrib-group><pub-date pub-type="ppub"><month>12</month><year>2003</year></pub-date><volume>4</volume><issue>3</issue><fpage>146</fpage><lpage>151</lpage><history><date date-type="received"><day>29</day><month>4</month><year>2002</year></date><date date-type="accepted"><day>17</day><month>7</month><year>2003</year></date></history><permissions><copyright-statement>&#x000a9; Springer-Verlag
Italia 2003</copyright-statement></permissions><abstract id="Abs1"><p>The purpose of this study was to determine the safety and
efficacy of botulinum toxin type A (BOTOX; Allergan, Irvine,
USA) in migraine prophylaxis. We performed a double-blind,
randomized, 90-day placebo-controlled study that enrolled 30
adult migraineurs. Patients received 50 units botulinum toxin
type A (n=15) or placebo (n=15). Outcome measures were monthly
frequency and duration of migraine attacks and the number of
severe attacks. Botulinum toxin type A produced significantly
greater reductions in the frequency of migraine attacks of any
severity at Day 90 (-3.14 vs. -0.53; <italic>p</italic>&#x0003c;0.05) and in the frequency of
severe migraine attacks at Days 60 (-1.4 vs. -0.54;
<italic>p</italic>&#x0003c;0.05) and 90 (-1.8 vs.
-0.20; <italic>p</italic>&#x0003c;0.02). One
patient in the botulinum toxin type A group experienced mild,
transient frontalis muscle weakness lasting approximately 30
days. Botulinum toxin type A injections were well tolerated and
provided effective migraine prophylaxis in these
patients.</p></abstract><kwd-group xml:lang="en"><title><bold>Key words</bold></title><kwd>Migraine</kwd><kwd>Botulinum toxin type A</kwd><kwd>Prophylaxis</kwd><kwd>Double blind</kwd><kwd>Placebo control</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag
Italia 2003</meta-value></custom-meta></custom-meta-group></article-meta></front></article>